

Carmelo Scarpignato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/308938/publications.pdf>

Version: 2024-02-01

313
papers

8,292
citations

53794

45
h-index

62596

80
g-index

332
all docs

332
docs citations

332
times ranked

7165
citing authors

#	ARTICLE	IF	CITATIONS
1	A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 801-811.	2.0	9
2	Review article: rethinking the "ladder" approach to reflux-like symptom management in the era of PPI resistance—a multidisciplinary perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1492-1500.	3.7	5
3	Non-Absorbable Antibiotics. , 2022, , 209-234.		1
4	COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. <i>Digestive Diseases</i> , 2021, 39, 119-139.	1.9	88
5	Management of perforated diverticulitis with generalized peritonitis. A multidisciplinary review and position paper. <i>Techniques in Coloproctology</i> , 2021, 25, 153-165.	1.8	16
6	Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers. <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 94-132.	0.8	11
7	Cancer Prevention in Patients with GERD and Barrett's Esophagus" <i>Medicine. Foregut</i> , 2021, 1, 50-62.	0.5	1
8	Editorial: acid suppression with potassium-competitive acid blockers dismissing genotype concerns. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 187-188.	3.7	4
9	Combined Treatment with Polynucleotides and Hyaluronic Acid Improves Tissue Repair in Experimental Colitis. <i>Biomedicines</i> , 2020, 8, 438.	3.2	14
10	Potential proton pump inhibitor-related adverse effects. <i>Annals of the New York Academy of Sciences</i> , 2020, 1481, 43-58.	3.8	24
11	Eosinophilic esophagitis: updates on key unanswered questions. <i>Annals of the New York Academy of Sciences</i> , 2020, 1481, 30-42.	3.8	4
12	Ageusia, gastrointestinal symptoms and marked asthenia in late December. A single case report with positive SARS-Cov2 IgG in Italy. <i>International Journal of Infectious Diseases</i> , 2020, 97, 352-353.	3.3	2
13	Pharmacologic treatment of GERD: Where we are now, and where are we going?. <i>Annals of the New York Academy of Sciences</i> , 2020, 1482, 193-212.	3.8	20
14	OC.08.3 THE "DICA" ENDOSCOPIC CLASSIFICATION FOR DIVERTICULAR DISEASE OF THE COLON SHOWS A SIGNIFICANT INTEROBSERVER AGREEMENT AMONG COMMUNITY ENDOSCOPISTS: AN INTERNATIONAL STUDY. <i>Digestive and Liver Disease</i> , 2020, 52, S27.	0.9	0
15	Gastrointestinal pharmacology: practical tips for the esophagologist. <i>Annals of the New York Academy of Sciences</i> , 2020, 1481, 90-107.	3.8	7
16	Colonic diverticular disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 20.	30.5	125
17	Addressing long-term PPI safety. <i>Digestive and Liver Disease</i> , 2020, 52, 853-856.	0.9	5
18	S1368 Vonoprazan-Based Dual Therapy and FDA-Approved H. pylori Eradication Regimens: A Comparison of the Available Pooled Data. <i>American Journal of Gastroenterology</i> , 2020, 115, S690-S691.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Eosinophilic Esophagitis: Diagnosis and Current Management. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 85-97.	0.9	19
20	Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity. <i>International Journal of Obesity</i> , 2019, 43, 331-343.	3.4	27
21	Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition. <i>Current Gastroenterology Reports</i> , 2019, 21, 55.	2.5	32
22	Editorial: potassium-competitive acid blockers for acid-related diseases—tegoprazan, a new kid on the block. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 960-962.	3.7	13
23	Towards an Effective and Safe Treatment of Inflammatory Pain: A Delphi-Guided Expert Consensus. <i>Advances in Therapy</i> , 2019, 36, 2618-2637.	2.9	53
24	Expert Consensus on Clinical Use of an Orally Administered Dexketoprofen Plus Tramadol Fixed-Dose Combination in Moderate-To-Severe Acute Pain: A Delphi Study. <i>Advances in Therapy</i> , 2019, 36, 3174-3185.	2.9	18
25	Antiemetic Drug Use in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 68, 466-471.	1.8	12
26	OC.03.3 THE "DICA" ENDOSCOPIC CLASSIFICATION FOR DIVERTICULAR DISEASE OF THE COLON SHOWS A SIGNIFICANT INTEROBSERVER AGREEMENT AMONG COMMUNITY ENDOSCOPISTS. <i>Digestive and Liver Disease</i> , 2019, 51, e84.	0.9	0
27	Gastric cancer prevention targeted on risk assessment: Gastritis OLGA staging. <i>Helicobacter</i> , 2019, 24, e12571.	3.5	20
28	The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. <i>Current Opinion in Gastroenterology</i> , 2019, 35, 344-355.	2.3	29
29	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2019, 51, 190-205.	0.9	77
30	Revisiting Montreal: New Insights into Symptoms and Their Causes, and Implications for the Future of GERD. <i>American Journal of Gastroenterology</i> , 2019, 114, 414-421.	0.4	35
31	Hot Topics in Medical Treatment of Diverticular Disease: Evidence Pro and Cons. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 23-29.	0.9	3
32	International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 57-66.	0.9	21
33	The "DICA" Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 23-27.	0.9	6
34	The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 39-44.	0.9	2
35	Course of the Diverticular Disease: What is changing?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 11-16.	0.9	1
36	Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs. <i>Gastroenterology</i> , 2018, 154, 500-514.	1.3	310

#	ARTICLE	IF	CITATIONS
37	P.06.20 GERD DIAGNOSIS IN 340 PATIENTS WITH ATYPICAL OR EXTRA-ESOPHAGEAL SYMPTOMS BY USING A NON INVASIVE SURROGATE TEST. <i>Digestive and Liver Disease</i> , 2018, 50, e187.	0.9	0
38	Impact of primary antibiotic resistance on the effectiveness of sequential therapy for <i>Helicobacter pylori</i> infection: lessons from a 5-year study on a large number of strains. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1261-1269.	3.7	43
39	Searching for a definition for pharmacologically refractory constipation: A systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 564-575.	2.8	14
40	P.06.26 RISK FACTORS IN GERD: A COMPARATIVE STUDY WITH DYSPEPTIC SUBJECTS ON 2300 PEOPLE IN A PRIMARY CARE SETTING. <i>Digestive and Liver Disease</i> , 2018, 50, e190.	0.9	0
41	OC.05.3 HOW CAN WE MEASURE ACID SECRETION IN THE SINGLE PATIENT? A VALIDATED NON-INVASIVE SURROGATE TEST COMPARED WITH MAXIMAL ACID OUTPUT IN 600 PEOPLE. <i>Digestive and Liver Disease</i> , 2018, 50, e79.	0.9	0
42	P.06.30 RISK FACTORS FOR ONSET OF ESOPHAGITIS IN A LONG 15 YEARS FOLLOW-UP. <i>Digestive and Liver Disease</i> , 2018, 50, e192.	0.9	0
43	Symptomatic Uncomplicated Diverticular Disease: Chronic Abdominal Pain in Diverticulosis Is Not Enough to Make the Diagnosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 2001-2002.	4.4	12
44	Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. <i>Frontiers in Pharmacology</i> , 2018, 9, 1340.	3.5	35
45	Potent Acid Suppression with PPIs and P-CABs: What's New?. <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 570-590.	0.8	37
46	Reply. <i>Gastroenterology</i> , 2018, 155, 1272-1273.	1.3	0
47	P.01.22 REFLUX ESOPHAGITIS AFTER H.P. ERADICATION: THE ROLE OF GASTRIC ACID SECRETION. <i>Digestive and Liver Disease</i> , 2018, 50, e128.	0.9	0
48	Mo1194 - Natural History of Gastric Ulcer in a 25 Years Follow-Up: Role of <i>Helicobacter Pylori</i> Infection and Nonsteroidal Anti-Inflammatory Drugs. <i>Gastroenterology</i> , 2018, 154, S-702.	1.3	0
49	P.06.23 EARLY GERD RELAPSE: A PROSPECTIVE ONE YEAR STUDY BY MEANS OF A NON-INVASIVE SURROGATE TEST. <i>Digestive and Liver Disease</i> , 2018, 50, e188-e189.	0.9	0
50	Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481877130.	3.2	33
51	Su1200 - Environmental Factors (Divorce, Job Changing, Night Shift Change): Critical Role in IBS Outcome. A Study on 110 Consecutive Patients. <i>Gastroenterology</i> , 2018, 154, S-501.	1.3	0
52	Tu1640 - The Clinical Outcome of Sudd: A 15-Years Prospective Study. <i>Gastroenterology</i> , 2018, 154, S-977-S-978.	1.3	0
53	Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks. , 2018, , 269-291.		3
54	Tu1315 - Is the Interval Between the first and the Second H.P. Eradication Therapy Relevant for the Success of the Cure? A Comparison Between One Week, One Month and One Year. <i>Gastroenterology</i> , 2018, 154, S-931.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Editorial: <i>Helicobacter pylori</i> resistance and sequential therapy—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 96-97.	3.7	3
56	Letter: can the overall gastrointestinal safety of celecoxib be extended to all COX-2 selective agents?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 108-110.	3.7	1
57	50 - Reflux Esophagitis after Helicobacter Pylori Eradication: The Role of Gastric Acid Secretion. <i>Gastroenterology</i> , 2018, 154, S-17.	1.3	0
58	P.01.12 FREQUENCY OF DIAGNOSIS OF ATROPHIC GASTRITIS IN A PRIMARY CARE SETTING: A POPULATION STUDY ON 10,000 PEOPLE. <i>Digestive and Liver Disease</i> , 2018, 50, e124.	0.9	0
59	Rifaximin for the Management of Colonic Diverticular Disease: far Beyond a Simple Antibiotic. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018, 27, 351-355.	0.9	6
60	Diagnosis and Treatment of Colonic Diverticular Disease: Position Paper of the Romanian Society of Gastroenterology and Hepatology. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018, 27, 449-457.	0.9	5
61	Rifaximin prevents diclofenac-induced enteropathy in rats through antibacterial and anti-inflammatory activities. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-5-28.	0.0	0
62	Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 604-616.	3.7	153
63	Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease—efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 631-642.	3.7	64
64	P.07.2: Natural History of Symptomatic Uncomplicated Diverticular Disease: A 13-Year Prospective Study. <i>Digestive and Liver Disease</i> , 2017, 49, e175-e176.	0.9	0
65	P.02.7: The Branded Proton Pump Inhibitors (PPIS) Increase Levels of Gastrin 17 (G-17) More than the Generic Ones in Dyspeptic Patients from an Italian Primary Care Population. <i>Digestive and Liver Disease</i> , 2017, 49, e140-e141.	0.9	0
66	P.01.7: Efficacy of PPIS and H-2 Blockers Therapy on Acid Suppression Assessed by Gastrin-17 and Pepsinogen I Serum Levels Determination in Gerd Patients. <i>Digestive and Liver Disease</i> , 2017, 49, e134.	0.9	0
67	Colonic Dysmotility Associated with High Fat Diet-Induced Obesity: Role of the Enteric Glia. <i>Gastroenterology</i> , 2017, 152, S180.	1.3	1
68	An expert consensus definition of failure of a treatment to provide adequate relief (PAR) for chronic constipation—an international Delphi survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 434-442.	3.7	11
69	P.02.18: Non Invasive Diagnosis of Upper Gi Diseases in a Primary Care Setting: A Study on 1,900 Patients. <i>Digestive and Liver Disease</i> , 2017, 49, e145.	0.9	0
70	Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol. <i>Current Medical Research and Opinion</i> , 2017, 33, 1165-1173.	1.9	60
71	Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans. <i>Gastroenterology</i> , 2017, 152, 980-982.e3.	1.3	57
72	P.02.1: Individual Assessment of Gastric Acid Production by Means of a Non-Invasive Test: Relationship Between Maximal Acid Output and Serum Pepsinogen I Levels in Patients with Different Upper GI Diseases. <i>Digestive and Liver Disease</i> , 2017, 49, e138.	0.9	0

#	ARTICLE	IF	CITATIONS
73	P.01.5: Serum Pepsinogen II as a Non-Invasive Marker for Diagnosis of Helicobacter Pylori Infection: A Prospective Study in a Cohort of Dyspeptic Patients. Digestive and Liver Disease, 2017, 49, e133.	0.9	0
74	P.01.11: Gastrin 17 in Singling out Patients with Different Pattern of Gastroesophageal Reflux: A Pilot Study using PH-Impedance as Reference Standard. Digestive and Liver Disease, 2017, 49, e136.	0.9	0
75	P.01.14: Overweight and Obesity as Risk Factors for Gerd Outcome: A 10 Years Study on a Gerd Population of 365 Patients. Digestive and Liver Disease, 2017, 49, e137.	0.9	0
76	P.02.2: Improvement of Symptoms in Patients Affected by Chronic Atrophic Gastritis: A 2 Years Prospective Study by using L-Cysteine (Acetium®,ϕ). Digestive and Liver Disease, 2017, 49, e138.	0.9	0
77	P.04.7: Ethinylestradiol/Levonorgestrel Oral Contraceptive and Acute Pancreatitis: A Case Series. Digestive and Liver Disease, 2017, 49, e155-e156.	0.9	1
78	Natural History of Symptomatic Uncomplicated Diverticular Disease: A 13-Year Prospective Study. Gastroenterology, 2017, 152, S807.	1.3	2
79	Non Invasive Diagnosis of Upper GI Diseases in a Primary Care Setting: A Study on 1,900 Patients. Gastroenterology, 2017, 152, S253-S254.	1.3	0
80	Recovery of Gastric Function in Chronic Atrophic Gastritis By Using L-Cysteine: A 3 Years Study. Gastroenterology, 2017, 152, S471.	1.3	0
81	P.02.8: Chronic Atrophic Gastritis is Related with an Increased Risk for Cardiovascular Diseases, Assessed by Homocysteine Serum Levels Determination. Digestive and Liver Disease, 2017, 49, e141.	0.9	0
82	P.02.9: Prevalence of Atrophic Gastritis in General Population: A Gastropanel®-Based Study, Compared with Olga Histological Classification. Digestive and Liver Disease, 2017, 49, e141.	0.9	0
83	OC.09.2: Appropriateness of PPI Administration in the Elderly: Evaluation of Acid Secretion and Atrophic Gastritis by Means of a Non-Invasive Test. Digestive and Liver Disease, 2017, 49, e99.	0.9	0
84	Gastrin 17 in Singling Out Patients with Different Patterns of Refluxate: A Pilot Study Using Impedance-pH as Reference Standard. Gastroenterology, 2017, 152, S653.	1.3	1
85	Reply. Gastroenterology, 2017, 153, 612-613.	1.3	1
86	Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors. Purinergic Signalling, 2017, 13, 497-510.	2.2	30
87	Individual Assessment of Gastric Acid Production by Means of a Non-Invasive Test: Relationship between Maximal Acid Output and Pepsinogen I Levels. Gastroenterology, 2017, 152, S471.	1.3	0
88	Efficacy of Rifaximin to Eradicate Small Intestine Bacterial Overgrowth and to Get Symptom Relief: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2017, 112, S647.	0.4	0
89	Constant Increase in Primary Resistances of Helicobacter pylori strains and Their Role in the Effectiveness of Sequential Therapy: A Lesson From a 5-Year Study. American Journal of Gastroenterology, 2017, 112, S664.	0.4	0
90	Non-invasive assessment of gastric secretory function in centenarians. Geriatric Care, 2017, 3, .	0.2	0

#	ARTICLE	IF	CITATIONS
91	Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine, 2016, 14, 179.	5.5	300
92	Probiotics for the Treatment of Symptomatic Uncomplicated Diverticular Disease. Journal of Clinical Gastroenterology, 2016, 50, S70-S73.	2.2	12
93	Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis. Journal of Clinical Gastroenterology, 2016, 50, S64-S69.	2.2	52
94	Current Management of Patients With Diverticulosis and Diverticular Disease. Journal of Clinical Gastroenterology, 2016, 50, S97-S100.	2.2	16
95	Unspecified Intestinal Malabsorption Associated with Angiotensin Receptor Blocker Therapy: Results from a Nationwide, Population-Based Study in Italy and Germany. Value in Health, 2016, 19, A509.	0.3	0
96	OC.07.3 RECOVERY OF GASTRIC FUNCTION AFTER ACETIUM® ADMINISTRATION: A 2 YEAR PROSPECTIVE STUDY IN PATIENTS WITH CHRONIC, ATROPHIC, BODY GASTRITIS. Digestive and Liver Disease, 2016, 48, e96.	0.9	0
97	Su1193 Rifaximin Prevents Enteric Bacteria Alterations and Inflammation in a Rat Model of Diclofenac-Induced Enteropathy. Gastroenterology, 2016, 150, S491-S492.	1.3	0
98	PC.01.2 PREDICTIVE VALUE OF THE –DICA–ENDOSCOPIC CLASSIFICATION ON THE OUTCOME OF THE DIVERTICULAR DISEASE OF THE COLON: AN INTERNATIONAL STUDY. Digestive and Liver Disease, 2016, 48, e68.	0.9	0
99	Adherence with regulatory resolutions on prevention of NSAIDs-related gastrointestinal injury in Italy. International Journal of Clinical Pharmacy, 2016, 38, 829-837.	2.1	4
100	Sa1408 Predictive Value of the –DICA–Endoscopic Classification on the Outcome of Diverticular Disease of the Colon: An International Study. Gastroenterology, 2016, 150, S307.	1.3	0
101	Adverse Effects of Nonsteroidal Anti-inflammatory Drugs on the Cardiovascular System. , 2016, , 61-89.		1
102	Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats. Journal of Controlled Release, 2016, 239, 203-210.	9.9	12
103	Management of Patients With Diverticulosis and Diverticular Disease. Journal of Clinical Gastroenterology, 2016, 50, S101-S107.	2.2	24
104	Preface to the Proceedings of the 2nd International Symposium on Diverticular Disease of the Colon. Journal of Clinical Gastroenterology, 2016, 50, S1-S1.	2.2	2
105	Prognostic Role of the Endoscopic Classification –DICA–. Journal of Clinical Gastroenterology, 2016, 50, S16-S19.	2.2	5
106	P.04.9 DIAGNOSIS OF CHRONIC ATROPHIC GASTRITIS IN PRIMARY CARE SETTING BY MEANS OF GASTROPANEL®: A POPULATION STUDY ON 10,000 CONSECUTIVE PATIENTS. Digestive and Liver Disease, 2016, 48, e146.	0.9	0
107	Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study. United European Gastroenterology Journal, 2016, 4, 604-613.	3.8	33
108	Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. Pharmacological Research, 2016, 104, 108-114.	7.1	52

#	ARTICLE	IF	CITATIONS
109	Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. <i>Pharmacological Research</i> , 2016, 104, 186-196.	7.1	30
110	Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. <i>Drug Development and Industrial Pharmacy</i> , 2016, 42, 332-339.	2.0	23
111	Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1.	4.3	24
112	Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e119.	2.5	61
113	Editorial: towards extended acid suppression - the search continues. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1027-1029.	3.7	14
114	307 Rifaximin for Prevention of NSAID-Associated Intestinal Lesions in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Video-Capsule Study. <i>Gastroenterology</i> , 2015, 148, S-68.	1.3	1
115	Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. <i>BMC Medicine</i> , 2015, 13, 55.	5.5	165
116	Development and Validation of an Endoscopic Classification of Diverticular Disease of the Colon: The DICA Classification. <i>Digestive Diseases</i> , 2015, 33, 68-76.	1.9	62
117	Comparing tapentadol to oxycodone/naloxone combination: building castles in the air. <i>Current Medical Research and Opinion</i> , 2015, 31, 335-338.	1.9	3
118	Involvement of the P2X7 Purinergic Receptor in Colonic Motor Dysfunction Associated with Bowel Inflammation in Rats. <i>PLoS ONE</i> , 2014, 9, e116253.	2.5	41
119	Gastrointestinal Drugs. <i>Side Effects of Drugs Annual</i> , 2014, 36, 539-560.	0.6	2
120	Editorial: hyponatremia - a possible but forgotten consequence of bowel preparation for colonoscopy. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1110-1112.	3.7	7
121	Role of the A_2B receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats. <i>British Journal of Pharmacology</i> , 2014, 171, 1314-1329.	5.4	26
122	Editorial: healing of refractory reflux oesophagitis – an ongoing unmet clinical need. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 987-989.	3.7	5
123	Editorial: adequate management may reduce the colorectal cancer risk associated with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 562-564.	3.7	3
124	P022 Role of P2X7 purinergic receptor in the control of enteric neuromuscular functions in normal rat distal colon and experimental bowel inflammation. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S73.	1.3	0
125	Sa1862 Are All Patients With Histological Diagnosis of Atrophic Gastritis Really At Risk of Developing Gastric Cancer? Assessment of Gastric Acid Production by Correlation Between Maximal Acid Output and Pepsinogen I. <i>Gastroenterology</i> , 2014, 146, S-314-S-315.	1.3	0
126	OC.05.4 CARDIAC SAFETY OF PRUCALOPRIDE IN RANDOMIZED CLINICAL TRIALS OF PATIENTS WITH CHRONIC CONSTIPATION. <i>Digestive and Liver Disease</i> , 2014, 46, S14.	0.9	1

#	ARTICLE	IF	CITATIONS
127	Su1951 Recovery of Gastric Function After Acetium Administration: A 6 Months Study in Atrophic Gastritis Subjects. <i>Gastroenterology</i> , 2014, 146, S-506.	1.3	0
128	Gastrointestinal drugs. <i>Side Effects of Drugs Annual</i> , 2014, 35, 633-658.	0.6	1
129	P.18.7 DOSE- AND TIME-DEPENDENT ERADICATION OF SMALL INTESTINE BACTERIAL OVERGROWTH (SIBO) WITH RIFAXIMIN: A META-ANALYTIC APPROACH. <i>Digestive and Liver Disease</i> , 2014, 46, S129.	0.9	0
130	Italian consensus conference for colonic diverticulosis and diverticular disease. <i>United European Gastroenterology Journal</i> , 2014, 2, 413-442.	3.8	141
131	Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 52, 125-131.	4.0	4
132	NSAID-Induced Enteropathy: Are the Currently Available Selective COX-2 Inhibitors All the Same?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 86-95.	2.5	44
133	OC.18.1 ARE ALL PATIENTS WITH HISTOLOGICAL DIAGNOSIS OF ATROPHIC GASTRITIS REALLY AT RISK OF DEVELOPING GASTRIC CANCER? ASSESSMENT OF GASTRIC ACID PRODUCTION BY CORRELATION BETWEEN MAXIMAL ACID OUTPUT AND PEPSINOGEN I. <i>Digestive and Liver Disease</i> , 2014, 46, S38-S39.	0.9	0
134	Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. <i>Pharmacological Research</i> , 2014, 85, 39-44.	7.1	31
135	OC.06.5 IS SEQUENTIAL THERAPY FOR ERADICATION OF HELICOBACTER PYLORI EQUALLY EFFECTIVE ALL OVER THE WORLD? A META-ANALYTIC APPROACH. <i>Digestive and Liver Disease</i> , 2014, 46, S17.	0.9	0
136	Long acting release-octreotide as "rescue" therapy to control angiodysplasia bleeding: A retrospective study of 98 cases. <i>Digestive and Liver Disease</i> , 2014, 46, 688-694.	0.9	36
137	Tu1181 Intermittent Versus Every-Day Mesalazine Therapy in Preventing Complications of Diverticular Disease: A Long-Term Follow-up Study. <i>Gastroenterology</i> , 2013, 144, S-782-S-783.	1.3	7
138	Global eradication rates for <i>Helicobacter pylori</i> infection: systematic review and meta-analysis of sequential therapy. <i>BMJ</i> , The, 2013, 347, f4587-f4587.	6.0	223
139	Poor effectiveness of PPIs in Non-Erosive Reflux Disease: the truth in the end!. <i>Neurogastroenterology and Motility</i> , 2013, 25, 707-707.	3.0	3
140	Commentary: towards an effective and safe treatment of small intestine bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1409-1410.	3.7	11
141	Caustic injury of the upper gastrointestinal tract: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2013, 19, 3918.	3.3	284
142	Piroxicam- β -Cyclodextrin: A GI Safer Piroxicam. <i>Current Medicinal Chemistry</i> , 2013, 20, 2415-2437.	2.4	36
143	Nonsteroidal Anti-Inflammatory Drug-Activated Gene-1 Plays a Role in the Impairing Effects of Cyclooxygenase Inhibitors on Gastric Ulcer Healing. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 342, 140-149.	2.5	14
144	Gastrointestinal drugs. <i>Side Effects of Drugs Annual</i> , 2012, 34, 555-578.	0.6	2

#	ARTICLE	IF	CITATIONS
145	Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease. <i>Internal and Emergency Medicine</i> , 2012, 7, 133-137.	2.0	18
146	Commentary: towards a cardiac safe prokinetic. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1243-1244.	3.7	7
147	Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end!. <i>Neurogastroenterology and Motility</i> , 2012, 24, 697-704.	3.0	41
148	Quantification of Serum Levels of Pepsinogens and Gastrin to Assess Eradication of Helicobacter Pylori. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 440-442.	4.4	23
149	P.1.193: MESALAMINE FOR THE MANAGEMENT OF PATIENTS WITH UNCOMPLICATED DIVERTICULAR DISEASE (SUDD): A 24 MONTHS PROSPECTIVE FOLLOW-UP STUDY. <i>Digestive and Liver Disease</i> , 2011, 43, S212.	0.9	0
150	Features and management of esophageal corrosive lesions in children in Sierra Leone: lessons learned from 175 consecutive patients. <i>Journal of Pediatric Surgery</i> , 2011, 46, 1739-1745.	1.6	19
151	P.1.288: PEPSINOGEN I, II, RATIO, AND G-17 IN PATIENTS WITH ESOPHAGITIS AND PATIENTS WITH EXTRA-ESOPHAGEAL MANIFESTATIONS OF GERD. <i>Digestive and Liver Disease</i> , 2011, 43, S244.	0.9	0
152	P.1.325: USEFULNESS OF SERUM PEPSINOGENS TO IDENTIFY CHRONIC ATROPHIC GASTRITIS. <i>Digestive and Liver Disease</i> , 2011, 43, S255-S256.	0.9	1
153	Gastrointestinal drugs. <i>Side Effects of Drugs Annual</i> , 2011, 33, 741-767.	0.6	2
154	Evaluation of Clinical Outcome after Laparoscopic Antireflux Surgery in Clinical Practice: Still a Controversial Issue. <i>Minimally Invasive Surgery</i> , 2011, 2011, 1-8.	0.5	8
155	Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 845-851.	1.6	26
156	Barrett's esophagus: proton pump inhibitors and chemoprevention II. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 114-139.	3.8	12
157	Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population. <i>Internal and Emergency Medicine</i> , 2011, 6, 35-39.	2.0	11
158	The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 818-822.	0.9	72
159	Pharmaceutical Principles of Acid Inhibitors: Unmet Needs. <i>Digestive Diseases</i> , 2011, 29, 469-475.	1.9	3
160	PWE-079...Use of antisecretory medication after antireflux surgery for patients with gastro-oesophageal reflux disease: a systematic review of non-randomised studies. <i>Gut</i> , 2010, 59, A116.3-A117.	12.1	1
161	Nonsteroidal Antiinflammatory Drug-Related Injury to the Gastrointestinal Tract: Clinical Picture, Pathogenesis, and Prevention. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 433-464.	2.2	190
162	P.10 "GASTROPANEL TEST" IN THE CLINICAL OUTCOME OF GERD: PROSPECTIVE SIX MONTHS CLINICAL STUDY. <i>Digestive and Liver Disease</i> , 2010, 42, S106.	0.9	0

#	ARTICLE	IF	CITATIONS
163	P.26 DIAGNOSTIC ACCURACY OF SERUM PEPSINOGENS AND GASTRIN IN THE FOLLOW-UP OF HELICOBACTER PYLORI INFECTION: A PILOT STUDY. <i>Digestive and Liver Disease</i> , 2010, 42, S112.	0.9	1
164	P.29 USEFULNESS OF NON INVASIVE TEST (GASTROPANEL) FOR SCREENING OF ATROPHIC GASTRITIS IN PATIENTS WITH AUTOIMMUNE THYROID DISEASE. <i>Digestive and Liver Disease</i> , 2010, 42, S113.	0.9	0
165	Rifaximin in the management of colonic diverticular disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 585-598.	3.0	25
166	New therapeutic approaches for management of sport-induced muscle strains. <i>Advances in Therapy</i> , 2009, 26, 1072-1083.	2.9	14
167	Myths and facts in the use of anti-inflammatory drugs. <i>Annals of Medicine</i> , 2009, 41, 423-437.	3.8	46
168	Corrosive oesophageal strictures in children: Outcomes after timely or delayed dilatation. <i>Digestive and Liver Disease</i> , 2009, 41, 263-268.	0.9	40
169	Caustic ingestion in children: is endoscopy always indicated? A perspective from a Sierra Leone experience. <i>Gastrointestinal Endoscopy</i> , 2009, 69, 1191-1192.	1.0	7
170	Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials. <i>Pharmacological Research</i> , 2009, 60, 254-263.	7.1	19
171	THE NATURAL HISTORY OF GASTRIC ULCER: A TWENTY-FOUR YEARS CLINICAL-ENDOSCOPICAL FOLLOW-UP. <i>Digestive and Liver Disease</i> , 2009, 41, S83.	0.9	0
172	Proton pump inhibitors in GORDAn overview of their pharmacology, efficacy and safety. <i>Pharmacological Research</i> , 2009, 59, 135-153.	7.1	156
173	Use of Antisecretory Medication after Antireflux Surgery for Patients with Gastroesophageal Reflux Disease (GERD): A Systematic Review of Randomized Control Trials (RCTs). <i>American Journal of Gastroenterology</i> , 2009, 104, S25.	0.4	4
174	Oesophageal corrosive injuries in children: a forgotten social and health challenge in developing countries. <i>Bulletin of the World Health Organization</i> , 2009, 87, 950-954.	3.3	72
175	A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 917-930.	3.7	201
176	OC3.07.1 CURCUMIN VS DOMPERIDON IN FUNCTIONAL DYSPEPSIA: BETTER THE PROKINETIC OR AN AGONIST OF VANILLOID RECEPTOR?. <i>Digestive and Liver Disease</i> , 2008, 40, S55.	0.9	0
177	PA.6 GASTRIN-17 (G-17): A SEROLOGICAL BIO-MARKER FOR DIAGNOSIS OF GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD). <i>Digestive and Liver Disease</i> , 2008, 40, S77-S78.	0.9	1
178	PA.28 SERUM PEPSINOGEN I AS NON INVASIVE MARKER OF GASTRIC ACID SECRETION. <i>Digestive and Liver Disease</i> , 2008, 40, S85-S86.	0.9	0
179	Proton pump inhibitors: the beginning of the end or the end of the beginning?. <i>Current Opinion in Pharmacology</i> , 2008, 8, 677-684.	3.5	72
180	NSAID-induced intestinal damage: are luminal bacteria the therapeutic target?. <i>Gut</i> , 2008, 57, 145-148.	12.1	56

#	ARTICLE	IF	CITATIONS
181	Corrosive esophageal injuries in children. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2007, 71, 1597-1604.	1.0	35
182	New drugs to suppress acid secretion: current and future developments. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2007, 4, 155-163.	0.5	6
183	Determinants of the short-term gastric damage caused by NSAIDs in man. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 95-106.	3.7	64
184	The burden of constipation on quality of life: results of a multinational survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 227-236.	3.7	303
185	Acid Suppression Therapy: Where Do We Go from Here?. <i>Digestive Diseases</i> , 2006, 24, 11-46.	1.9	87
186	Experimental and Clinical Pharmacology of Rifaximin, a Gastrointestinal Selective Antibiotic. <i>Digestion</i> , 2006, 73, 13-27.	2.3	108
187	Dysphagia aortica: A neglected symptom of aorto-esophageal fistula. <i>Digestive and Liver Disease</i> , 2006, 38, 51-54.	0.9	12
188	Review article: the opportunities and benefits of extended acid suppression. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 23-34.	3.7	34
189	Advances in GI Pharmacology and Therapeutics. <i>Digestive Diseases</i> , 2006, 24, 7-10.	1.9	2
190	Rescue Therapies for the Management of <i>Helicobacter pylori</i> Infection. <i>Digestive Diseases</i> , 2006, 24, 113-130.	1.9	49
191	Eradication of <i>Helicobacter pylori</i> : Are Rifaximin-Based Regimens Effective?. <i>Digestion</i> , 2006, 73, 129-135.	2.3	25
192	Treatment of Functional Bowel Disorders: Is There Room for Antibiotics?. <i>Digestion</i> , 2006, 73, 38-46.	2.3	18
193	Management of Colonic Diverticular Disease. <i>Digestion</i> , 2006, 73, 58-66.	2.3	31
194	Microbial Flora in NSAID-Induced Intestinal Damage: A Role for Antibiotics?. <i>Digestion</i> , 2006, 73, 136-150.	2.3	79
195	Rifaximin, a Peculiar Rifamycin Derivative: Established and Potential Clinical Use Outside the Gastrointestinal Tract. <i>Chemotherapy</i> , 2005, 51, 122-130.	1.6	20
196	Antisecretory drugs, <i>Helicobacter pylori</i> infection and symptom relief in GORD: Still an unexplored triangle. <i>Digestive and Liver Disease</i> , 2005, 37, 468-474.	0.9	10
197	Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential. <i>Chemotherapy</i> , 2005, 51, 36-66.	1.6	201
198	Myths and Misconceptions About Chronic Constipation. <i>American Journal of Gastroenterology</i> , 2005, 100, 232-242.	0.4	459

#	ARTICLE	IF	CITATIONS
199	Antisecretory Drugs for Eradication of <i>Helicobacter pylori</i> : Antibacterial Activity and Synergism with Antimicrobial Agents. , 2004, 11, 134-178.		0
200	Does the learning phase influence the late outcome of patients with gastroesophageal reflux disease after laparoscopic fundoplication?. Surgical Endoscopy and Other Interventional Techniques, 2004, 18, 266-271.	2.4	8
201	Towards the ideal regimen for <i>Helicobacter pylori</i> eradication: the search continues. Digestive and Liver Disease, 2004, 36, 243-247.	0.9	17
202	Can Gangrenous Cholecystitis be Prevented?. Journal of Clinical Gastroenterology, 2004, 38, 710-716.	2.2	26
203	Endoscopic treatment of gastro-oesophageal reflux disease (GORD): a systematic review. Digestive and Liver Disease, 2003, 35, 818-838.	0.9	20
204	Early esophageal transit study after laparoscopic fundoplication: how useful is it?. American Journal of Surgery, 2002, 183, 226-231.	1.8	9
205	Dysphagia and Clinical Outcome after Laparoscopic Nissen or Rossetti Fundoplication: Sequential Prospective Study. World Journal of Surgery, 2002, 26, 1106-1111.	1.6	17
206	Quality of life for patients with gastroesophageal reflux disease 2 years after laparoscopic fundoplication. Surgical Endoscopy and Other Interventional Techniques, 2002, 16, 1555-1560.	2.4	29
207	Improving opportunities for effective management of gastro-oesophageal reflux disease. Digestive and Liver Disease, 2001, 33, 720-730.	0.9	5
208	Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Digestive and Liver Disease, 2001, 33, 600-606.	0.9	28
209	New therapeutic modalities for benign oesophageal disease: an overview. Digestive and Liver Disease, 2001, 33, 260-265.	0.9	4
210	Current trends in the management of achalasia. Digestive and Liver Disease, 2001, 33, 266-277.	0.9	27
211	Somatostatin Analogs for Cancer Treatment and Diagnosis: An Overview. Chemotherapy, 2001, 47, 1-29.	1.6	76
212	Different affinity states of CCK1 receptors on pancreatic acini and gastric smooth muscle in the rat. Journal of Physiology (Paris), 2001, 95, 391-398.	2.1	4
213	Management of Irritable Bowel Syndrome: Novel Approaches to the Pharmacology of Gut Motility. Canadian Journal of Gastroenterology & Hepatology, 1999, 13, 50A-65A.	1.7	54
214	Somatostatin for Upper Gastrointestinal Hemorrhage and Pancreatic Surgery. Digestion, 1999, 60, 1-16.	2.3	63
215	Bismuth Compounds for Eradication of <i>Helicobacter pylori</i> : Pharmacology and Safety. , 1999, 11, 87-127.		11
216	Antisecretory Drugs for Eradication of <i>Helicobacter pylori</i> : Antibacterial Activity and Synergism with Antimicrobial Agents. , 1999, 11, 136-181.		11

#	ARTICLE	IF	CITATIONS
217	Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1999, 31 Suppl 1, S63-72.	0.5	16
218	Different actions of CCK on pancreatic and gastric growth in the rat: effect of CCKA receptor blockade. <i>British Journal of Pharmacology</i> , 1998, 124, 435-440.	5.4	19
219	DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: Thirteen-year follow-up study on a cohort of patients. <i>Cytometry</i> , 1998, 34, 257-263.	1.8	83
220	Effects of tablet and effervescent formulations of ranitidine 75µmg and cimetidine 200µmg on gastric acidity and oesophageal acid exposure in healthy humans. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 1155-1161.	3.7	9
221	Effect of loxiglumide on lower esophageal sphincter motor events and gastric relaxation induced by duodenal infusion of a liquid meal in healthy subjects. <i>Gastroenterology</i> , 1998, 114, A863.	1.3	1
222	Fortnightly review: Treatment of gastro-oesophageal reflux disease in adults. <i>BMJ: British Medical Journal</i> , 1998, 316, 1720-1723.	2.3	70
223	Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 275, G1266-G1273.	3.4	56
224	Pharmacological Stimulation of Gastrointestinal Motility: Where We Are and Where Are We Going?. <i>Digestive Diseases</i> , 1997, 15, 112-136.	1.9	17
225	Specific adaptation of gastric emptying to diets with differing protein content in the rat: is endogenous cholecystokinin implicated?. <i>Gut</i> , 1997, 41, 612-618.	12.1	38
226	Functional Ultrasonography of the Digestive Tract. , 1997, 24, 342-383.		1
227	Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat. <i>Journal of Physiology (Paris)</i> , 1997, 91, 257-264.	2.1	3
228	The Management of Nonvariceal Upper Digestive Bleeding: Is There a Role for Somatostatin and Its Analogues?. <i>Progress in Basic and Clinical Pharmacology</i> , 1996, 10, 139-150.	0.1	0
229	Camostatate- and caerulein-induced delay of gastric emptying in the rat: effect of CCK receptor antagonists. <i>European Journal of Pharmacology</i> , 1996, 306, 153-159.	3.5	17
230	The Place of Octreotide in the Medical Management of the Dumping Syndrome. <i>Digestion</i> , 1996, 57, 114-118.	2.3	21
231	Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo.. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 411-419.	3.7	35
232	Inhibition of acetylcholine induced intestinal motility by interleukin 1 beta in the rat.. <i>Gut</i> , 1996, 39, 470-474.	12.1	52
233	In vitro contractile effects of short chain fatty acids in the rat terminal ileum.. <i>Gut</i> , 1996, 38, 53-58.	12.1	39
234	Oesophageal sensitivity to acid in patients with non-cardiac chest pain: is the oesophagus hypersensitive?. <i>European Journal of Gastroenterology and Hepatology</i> , 1995, 12, 1152-1159.	1.6	14

#	ARTICLE	IF	CITATIONS
235	Transmucosal Potential Difference as an Index of Esophageal Mucosal Integrity. <i>Digestion</i> , 1995, 56, 51-60.	2.3	15
236	Prevention of NSAID-induced Gastroduodenal Mucosal Injury: Meta-Analysis of Clinical Trials with Misoprostol and H ₂ -Receptor Antagonists. <i>Digestive Diseases</i> , 1995, 13, 62-74.	1.9	29
237	A new technique for continuous measurement and recording of gastric potential difference in the rat: Evaluation of NSAID-induced gastric mucosal damage. <i>Journal of Pharmacological and Toxicological Methods</i> , 1995, 34, 63-72.	0.7	13
238	Reflux related symptoms in patients with normal oesophageal exposure to acid.. <i>Gut</i> , 1995, 37, 457-464.	12.1	223
239	Nonsteroidal Anti-Inflammatory Drugs: How Do They Damage Gastroduodenal Mucosa?. <i>Digestive Diseases</i> , 1995, 13, 9-39.	1.9	50
240	Prevention and Treatment of Traveler's Diarrhea: A Clinical Pharmacological Approach (Part 1 of 2). <i>Chemotherapy</i> , 1995, 41, 48-62.	1.6	50
241	Distinct receptors mediate gastrin-releasing peptide and neuromedin B-induced delay of gastric emptying of liquids in rats. <i>European Journal of Pharmacology</i> , 1995, 286, 109-112.	3.5	22
242	Gastric Emptying in Gastroesophageal Reflux Disease and Other Functional Esophageal Disorders. <i>Frontiers of Gastrointestinal Research</i> , 1994, 22, 223-259.	0.1	9
243	Esophageal pH Monitoring. <i>Frontiers of Gastrointestinal Research</i> , 1994, 22, 71-108.	0.1	20
244	Placebo and Placebo Effect: Their Impact on the Evaluation of Drug Response in Patients. <i>Digestive Diseases</i> , 1994, 12, 368-377.	1.9	19
245	Effect of CCK and its antagonists on gastric emptying. <i>Journal of Physiology (Paris)</i> , 1993, 87, 291-300.	2.1	42
246	Cholecystokinin Antagonists and Motilides: Pharmacology and Potential in the Treatment of Gastroesophageal Reflux Disease and Other Digestive Motor Disorders. <i>Frontiers of Gastrointestinal Research</i> , 1992, 20, 90-128.	0.1	9
247	Sucralfate and Other Mucosal Protective Compounds: Pharmacology and Potential in the Treatment of Esophageal Lesions. <i>Frontiers of Gastrointestinal Research</i> , 1992, 20, 317-346.	0.1	4
248	Acid-Lowering Drugs in the Treatment of Gastroesophageal Reflux Disease: An Overview. <i>Frontiers of Gastrointestinal Research</i> , 1992, 20, 129-152.	0.1	0
249	Metoclopramide: Is There Still a Place in the Treatment of Gastroesophageal Reflux Disease?. <i>Frontiers of Gastrointestinal Research</i> , 1992, 20, 17-29.	0.1	0
250	Antacids and Alginates in the Treatment of Gastroesophageal Reflux Disease: How Do They Work and How Much Are They Clinically Useful?. <i>Frontiers of Gastrointestinal Research</i> , 1992, 20, 153-181.	0.1	4
251	Clinical Pharmacology of Active Variceal Bleeding. <i>Digestive Diseases</i> , 1992, 10, 16-29.	1.9	7
252	Effect of devazepide on caerulein and camostatate induced delay of gastric emptying in the rat. <i>Pharmacological Research</i> , 1992, 25, 288-289.	7.1	2

#	ARTICLE	IF	CITATIONS
253	Effect of cisapride on gastric emptying of solids and postprandial esophageal exposure to acid in healthy volunteers. <i>Pharmacological Research</i> , 1992, 25, 212-213.	7.1	1
254	Effect of nizatidine on salivary secretion in the rat. <i>Pharmacological Research</i> , 1992, 25, 286-287.	7.1	0
255	Gastroesophageal reflux disease and pH monitoring. <i>Current Opinion in Gastroenterology</i> , 1990, 6, 608-620.	2.3	2
256	Columnar-lined (Barrett's) esophagus. <i>Current Opinion in Gastroenterology</i> , 1990, 6, 580-585.	2.3	2
257	Simultaneous Measurement and Recording of Gastric Potential Difference and Intragastric pH in Man. <i>Digestive Diseases</i> , 1990, 8, 60-70.	1.9	6
258	Gastric Emptying Measurement in Man. <i>Frontiers of Gastrointestinal Research</i> , 1990, 17, 198-246.	0.1	21
259	Bombesin-induced pancreatic secretion and growth in rats: effect of proglumide, spantide and ranitidine. <i>International Journal of Tissue Reactions</i> , 1990, 12, 299-307.	0.2	2
260	Inhibition of caerulein-induced gall bladder emptying by cimetropium bromide in humans. <i>European Journal of Clinical Pharmacology</i> , 1989, 37, 483-486.	1.9	3
261	Some evidence for central A2 receptors that inhibit acid secretion in the rat. <i>Pharmacological Research</i> , 1989, 21, 491-491.	7.1	0
262	Dual effect of bombesin and gastrin releasing peptide on gastric emptying in conscious cats. <i>Peptides</i> , 1989, 10, 281-287.	2.4	4
263	PANCREATIC SECRETORY AND TROPHIC RESPONSE TO CAERULEIN IN RATS: EFFECT OF PROGLUMIDE AND LORGLUMIDE. <i>Fundamental and Clinical Pharmacology</i> , 1989, 3, 295-306.	1.9	4
264	Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the rat. <i>British Journal of Pharmacology</i> , 1989, 96, 661-669.	5.4	26
265	Effect of cimetropium bromide and other antispasmodic compounds on in vitro guinea-pig gallbladder. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 1989, 11, 323-9.	0.8	3
266	Mucosal protective agents: why forget pirenzepine?. <i>Digestive Diseases and Sciences</i> , 1988, 33, 1500-1500.	2.3	0
267	Effect of Bombesin on Insulin Release in Man. <i>Annals of the New York Academy of Sciences</i> , 1988, 547, 527-529.	3.8	1
268	Different effects of bombesin on glucose- and tolbutamide-induced insulin release in man. <i>British Journal of Pharmacology</i> , 1988, 94, 1023-1028.	5.4	3
269	Pharmacological Bases of the Medical Treatment of Gastroesophageal Reflux Disease. <i>Digestive Diseases</i> , 1988, 6, 117-148.	1.9	19
270	Effect of Bombesin and Its Mammalian Counterpart, GRP, on Exocrine Pancreas in the Rat. <i>Digestion</i> , 1988, 41, 229-236.	2.3	12

#	ARTICLE	IF	CITATIONS
271	Caerulein in supramaximal doses fails to stimulate pancreatic growth, but it forces secretory granulopoiesis. <i>Acta Physiologica Hungarica</i> , 1988, 71, 99-106.	0.9	6
272	Effect of Bombesin on Glucose-Induced Insulin Release in Humans. <i>Digestion</i> , 1987, 37, 114-124.	2.3	6
273	Relaxant effect of the H ₂ -receptor antagonist oxmetidine on guinea pig and human airways. <i>British Journal of Pharmacology</i> , 1987, 90, 523-530.	5.4	4
274	Antisecretory and antiulcer effect of the H ₂ -receptor antagonist famotidine in the rat: comparison with ranitidine. <i>British Journal of Pharmacology</i> , 1987, 92, 153-159.	5.4	16
275	Bombesin: An insulinotropic peptide in humans. <i>Regulatory Peptides</i> , 1987, 19, 136.	1.9	1
276	Are H ₂ -receptors involved in the physiological regulation of gastric emptying?. <i>American Journal of Physiology - Renal Physiology</i> , 1987, 252, G719-G720.	3.4	0
277	Inhibition of Gastric Acid Secretion by Adenosine Receptor Stimulation in the Rat. <i>Pharmacology</i> , 1987, 34, 264-268.	2.2	19
278	Bombesin promotes pancreatic growth in suckling rats. <i>Experientia</i> , 1987, 43, 201-202.	1.2	13
279	Effect of famotidine and ranitidine on gastric secretion and emptying in the rat. <i>Drug Development Research</i> , 1987, 11, 37-43.	2.9	2
280	Effect of somatostatin 14 on pure human pancreatic secretion. <i>Digestive Diseases and Sciences</i> , 1987, 32, 1065-1070.	2.3	37
281	Bombesin inhibits growth hormone response to insulin-induced hypoglycemia in humans. <i>Brain Research</i> , 1986, 371, 187-189.	2.2	8
282	Cimetidine Inhibition of Dimaprit-Induced Writhing in the Rat. <i>Pharmacology</i> , 1986, 32, 237-240.	2.2	3
283	The Effect of the New H ₂ -Receptor Antagonist Mifentidine on Gastric Secretion, Gastric Emptying and Experimental Gastric and Duodenal Ulcers in the Rat: Comparison with Cimetidine and Ranitidine. <i>Digestion</i> , 1986, 33, 7-16.	2.3	15
284	Effect of somatostatin and thyrotropin-releasing hormone on cholecystokinin-induced gallbladder emptying. <i>Digestive Diseases and Sciences</i> , 1986, 31, 1345-1350.	2.3	27
285	Oxygen free radicals interact with indomethacin to cause gastrointestinal injury. <i>Agents and Actions</i> , 1986, 17, 484-488.	0.7	64
286	Effect of Bombesin on Basal and Stimulated Secretion of Some Pituitary Hormones in Humans. <i>Hormone Research</i> , 1986, 23, 129-135.	1.8	15
287	Effect of Caerulein on Pituitary Response to TRH in Humans. <i>Hormone Research</i> , 1986, 24, 295-301.	1.8	2
288	Opposite effects of bombesin on insulin and gastrin response to food in humans.. <i>Gut</i> , 1986, 27, 499-504.	12.1	5

#	ARTICLE	IF	CITATIONS
289	Inhibition of Pancreatic Secretory and Trophic Response to Caerulein by the H ₂ -Receptor Antagonist Ranitidine in the Rat. <i>Digestion</i> , 1985, 31, 177-182.	2.3	9
290	Comparative effects of vasoactive intestinal peptide and secretin on exocrine pancreatic secretion in the cat. <i>Regulatory Peptides</i> , 1985, 12, 125-132.	1.9	2
291	Inhibition of the Histamine-Stimulated Adenylate Cyclase Activity of Guinea Pig Gastric Cells by the H ₂ -Receptor Antagonists Cimetidine, Oxmetidine and SKF 93479. <i>Pharmacology</i> , 1984, 28, 268-274.	2.2	8
292	Bombesin and Gastric Emptying. <i>Gastroenterology</i> , 1984, 86, 1629-1630.	1.3	2
293	Plasma levels and renal removal of gastrin after acute hepatic ischemia in dogs. <i>Journal of Endocrinological Investigation</i> , 1984, 7, 201-205.	3.3	1
294	Inhibition of gastric emptying and secretion by pirenzepine and atropine in rats. <i>European Journal of Pharmacology</i> , 1984, 101, 193-200.	3.5	17
295	Inhibition of Gastric Emptying by Angiotensin in the Rat and its Antagonism by Saralasin. <i>Journal of Urology</i> , 1984, 131, 1025-1025.	0.4	0
296	Effects of Bombesin on Gastric Emptying of Solids in Normal and Antrectomized Subjects: Evidence for an Action at the Distal Stomach. , 1984, , 149-156.		1
297	Impaired TSH response to TRH after intravenous ranitidine in man. <i>Experientia</i> , 1983, 39, 109-110.	1.2	6
298	Renal removal of glucagon and insulin after acute hepatic ischaemia in dogs. <i>Diabète & Métabolisme</i> , 1983, 9, 3-8.	0.3	3
299	Inhibition of Gastric Emptying by Bombesin in Man. <i>Digestion</i> , 1982, 23, 128-131.	2.3	28
300	HISTAMINE H ₂ -ANTAGONISTS MODIFY GASTRIC EMPTYING IN THE RAT. <i>British Journal of Pharmacology</i> , 1982, 77, 443-448.	5.4	50
301	Ranitidine delays gastric emptying of solids in man.. <i>British Journal of Clinical Pharmacology</i> , 1982, 13, 252-253.	2.4	21
302	Different effects of the H ₂ -antagonists on gastric emptying in the rat. <i>Experientia</i> , 1982, 38, 385-386.	1.2	10
303	Different effects of cimetidine and ranitidine on gastric emptying in rats and man. <i>Agents and Actions</i> , 1982, 12, 172-173.	0.7	25
304	EFFECT OF SUBSTANCE P AND ITS NATURAL ANALOGUES ON GASTRIC EMPTYING OF THE CONSCIOUS RAT. <i>British Journal of Pharmacology</i> , 1981, 72, 221-223.	5.4	20
305	The effect of bombesin on gastric emptying of solids in man. <i>Peptides</i> , 1981, 2, 199-203.	2.4	14
306	Effects of Alkyl Analogues of Histamine and Metiamide on the Isolated Guinea Pig Heart. <i>Pharmacology</i> , 1981, 22, 101-107.	2.2	10

#	ARTICLE	IF	CITATIONS
307	Failure of Drugs Acting on H(2)-Receptors to Modify Plasma Prolactin Levels in Pituitary Adenomas: Evidence for a Suprapituitary Locus of Action. <i>International Pharmacopsychiatry</i> , 1981, 16, 79-83.	0.4	0
308	Effect of Histamine and Related Compounds on Gastric Emptying of the Conscious Rat. <i>Pharmacology</i> , 1981, 23, 185-191.	2.2	14
309	Effect of Acute and Chronic Cimetidine Administration on Glucose Tolerance and Insulin Secretion in Man. <i>Hormone Research</i> , 1981, 15, 228-236.	1.8	6
310	Bombesin Delays Gastric Emptying in the Rat. <i>Digestion</i> , 1981, 21, 104-106.	2.3	45
311	Caerulein delays gastric emptying of solids in man. <i>Archives Internationales De Pharmacodynamie Et De Therapie</i> , 1981, 249, 98-105.	0.2	8
312	Action of caerulein on gastric emptying of the conscious rat. <i>Archives Internationales De Pharmacodynamie Et De Therapie</i> , 1980, 246, 286-94.	0.2	70
313	Effects of Cimetidine on the Secretion of Some Pituitary Hormones. <i>Pharmacology</i> , 1979, 19, 111-115.	2.2	7